Anti-Xa Assay
Specimen Volume
3.5 mL (Vacuette tubes) or 2.7mL (BD Vacutainer tubes)Specimen Transport
Standard transport to laboratory - State for the attention of Special Coagulation on request formSample Preparation
Turnaround Time
7 days (Unless urgent by prior arrangement with laboratory)Sample Processing In Laboratory
Sample should be centrifugedSample Stability
12 hours from venepuncture (ideally received no later than 4 hours after collection)General Information
Test Availability:
Queen Elizabeth and Heartlands sites: LMWH
Queen Elizabeth site only: UFH, Apixaban, Rivaroxaban, Fondaparinux
Heartlands site only: Edoxaban
Samples received at each site will be sent on to the appropriate laboratory for testing.
For urgent special coagulation assay information click Here
External Requests:
Note: For external requests please click Here for Coagulation Disorders request form. Please complete all information fully.
Sample packing and transportation:
Frozen plasma should be sent on dry ice using an insulated container to ensure that it remains frozen during transport. Please refer to the preanalytical variables section of the BSH guidelines on the laboratory aspects of assays used in haemostasis and thrombosis1.
As an alternative the bio-freeze container system can be used to ensure samples remain frozen in transit. These have been locally validated to maintain samples at -20oC for up to 12 hours providing they have been preconditioned in a -80oC freezer for 24 hours prior to use.
IMPORTANT: If sending samples to more than one department separate transport containers must be used. DO NOT package samples for different departments in the same container. This may lead to a loss of sample integrity when samples have to be unpacked and distributed to multiple departments.
Address:
Transport containers should be specifically labelled to ensure they are delivered to the correct location:
For Queen Elizabeth Hospital:
Special Coagulation, Haematology Laboratory, Clinical Laboratory Services, Level -1, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW.
For Heartlands Hospital:
Haematology Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS.
Disclaimer:
Please note failure to use an appropriate transit container may affect sample integrity, thus the accuracy of results cannot be guaranteed. Furthermore, samples packaged incorrectly that arrive in a thawed state cannot be tested.
Please contact the laboratory on 0121 371 5988 (Queen Elizabeth Hospital) or 0121 424 0908 (Heartlands Hospital) if you require any further information.
1) Baker, P., Platton, S., Gibson, C., Gray, E., Jennings, I., Murphy, P., Laffan, M. and British Society for Haematology, Haemostasis and Thrombosis Task Force (2020), Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br. J. Haematol., 191: 347-362.
https://doi.org/10.1111/bjh.16776
Samples that meet the following criteria will not be processed:
- Haemolysed, clotted, underfilled or overfilled samples.
- Samples >12 hours old from the time of collection.
- Samples received from other hospital laboratories that have been frozen and thawed.
- Samples which fail the minimum data set.
Assay Limitations:
- For accurate results samples should be collected 3-4 hours post dose, when the concentration in the blood is expected to be at peak level.
- Random and trough anti-Xa tests may also be requested when there are concerns that the anticoagulant may be accumulating e.g. in renal failure.
- If heparin is being given by continuous venous infusion, samples can be taken at any time but they must be taken from the other arm.
For more information please see https://labtestsonline.org.uk/tests/heparin-anti-xa
Notes
Please state anticoagulant on request form e.g. LMWH, UFH, Apixaban, Rivaroxaban, Fondaparinux or Edoxaban. Samples must be collected 4 hours post dose.
LMWH: Samples should be taken 4 hours after subcutaneous injection, once steady state has been achieved after administration of at least three doses.
Reference Range
LMWH:
Prophylactic Reference Range 0.1-0.3 IU/mL
Therapeutic Range 0.5-1.0 IU/mL
Therapeutic range for mechanical heart valve during pregnancy 1.0-1.4 IU/mL
Rivaroxaban:
Stroke prevention in NVAF 20mg OD 184-343ng/mL[1]
Treatment of PE/DVT 20mg OD 189-419ng/mL[1]
Treatment of PE/DVT 10mg OD 7-273ng/mL[2]
Treatment of ACS 2.5mg OD 13-123ng/mL[2]
Apixaban:
Stroke prevention in NVAF 5mg BD 91-321ng/mL[1]
Stroke prevention in NVAF 2.5mg BD 69-221ng/mL[2]
Treatment of PE/DVT 10mg BD 111-572ng/mL[2]
Treatment of PE/DVT 5mg BD 59-302ng/mL[1]
Treatment of PE/DVT 2.5mg BD 30-153ng/mL[2]
Fondaparinux:
2.5mg OD 0.39-0.50ug/mL[1]
7.5mg OD 1.20-1.26ug/ml[1]
Edoxaban:
Stroke prevention in NVAF 60mg OD 125-245ng/mL[1]
Treatment of PE/DVT 60mg OD 149-317ng/mL[1]
Stroke prevention in NVAF 30mg OD 55-120ng/mL[2]
Treatment of PE/DVT 30mg OD 99-125ng/mL[2]
[1] Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline, Baker et al, Brit J Haematol, 2024
[2] Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulant, Douxfils et al, Thromb Haemost, 2021
Specifications
- EQA Status: NEQAS / ECAT
- EQAS Scheme: Yes
